Clinical Trials Logo

Recurrent Esophageal Carcinoma clinical trials

View clinical trials related to Recurrent Esophageal Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01142388 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Start date: September 21, 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.